Genomically driven breast cancer trial: Ready to play?
This article was originally published in Scrip
Executive Summary
Just as an FDA-convened 21 October workshop was winding down after a day full of rapid-fire presentations and thought-provoking discussions about how to go about putting together a global collaboration for an international genomically driven master protocol trial to simultaneously test several targeted breast cancer drugs in multiple treatment arms, a new debate erupted about how to ensure the meeting does not simply lead to more talk and no action.